Vasily Giannakeas1,2,3, David W Lim1, Steven A Narod4,5,6. 1. Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada. 2. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. 3. ICES, Toronto, ON, Canada. 4. Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada. steven.narod@wchospital.ca. 5. Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. steven.narod@wchospital.ca. 6. Institute of Medical Science, University of Toronto, Toronto, ON, Canada. steven.narod@wchospital.ca.
Abstract
BACKGROUND: We sought to estimate the annual risk and 25-year cumulative risk of contralateral breast cancer among women with stage 0-III unilateral breast cancer. METHODS: We identified 812,851 women with unilateral breast cancer diagnosed between 1990 and 2015 in the SEER database and followed them for contralateral breast cancer for up to 25 years. Women with a known bilateral mastectomy were excluded. We calculated the annual risk of contralateral breast cancer by age at diagnosis, by time since diagnosis and by current age. We compared risks by ductal carcinoma in situ (DCIS) versus invasive disease, by race and by oestrogen receptor (ER) status of the first cancer. RESULTS: There were 25,958 cases of contralateral invasive breast cancer diagnosed (3.2% of all patients). The annual risk of contralateral breast cancer over the 25-year follow-up period was 0.37% and the 25-year actuarial risk of contralateral invasive breast cancer was 9.9%. The annual risk varied to a small degree by age of diagnosis, by time elapsed since diagnosis and by current age. The 25-year actuarial risk was similar for DCIS and invasive breast cancer patients (10.1 versus 9.9%). The 25-year actuarial risk was higher for black women (12.7%) than for white women (9.7%) and was lower for women with ER-positive breast cancer (9.5%) than for women with ER-negative breast cancer (11.2%). CONCLUSIONS: Women with unilateral breast cancer experience an annual risk of contralateral breast cancer ~0.4% per year, which persists over the 25-year follow-up period.
BACKGROUND: We sought to estimate the annual risk and 25-year cumulative risk of contralateral breast cancer among women with stage 0-III unilateral breast cancer. METHODS: We identified 812,851 women with unilateral breast cancer diagnosed between 1990 and 2015 in the SEER database and followed them for contralateral breast cancer for up to 25 years. Women with a known bilateral mastectomy were excluded. We calculated the annual risk of contralateral breast cancer by age at diagnosis, by time since diagnosis and by current age. We compared risks by ductal carcinoma in situ (DCIS) versus invasive disease, by race and by oestrogen receptor (ER) status of the first cancer. RESULTS: There were 25,958 cases of contralateral invasive breast cancer diagnosed (3.2% of all patients). The annual risk of contralateral breast cancer over the 25-year follow-up period was 0.37% and the 25-year actuarial risk of contralateral invasive breast cancer was 9.9%. The annual risk varied to a small degree by age of diagnosis, by time elapsed since diagnosis and by current age. The 25-year actuarial risk was similar for DCIS and invasive breast cancer patients (10.1 versus 9.9%). The 25-year actuarial risk was higher for black women (12.7%) than for white women (9.7%) and was lower for women with ER-positive breast cancer (9.5%) than for women with ER-negative breast cancer (11.2%). CONCLUSIONS: Women with unilateral breast cancer experience an annual risk of contralateral breast cancer ~0.4% per year, which persists over the 25-year follow-up period.
Authors: Kelly K Hunt; David M Euhus; Judy C Boughey; Anees B Chagpar; Sheldon M Feldman; Nora M Hansen; Swati A Kulkarni; David R McCready; Eleftherios P Mamounas; Lee G Wilke; Kimberly J Van Zee; Monica Morrow Journal: Ann Surg Oncol Date: 2016-12-08 Impact factor: 5.344
Authors: Iris Kramer; Michael Schaapveld; Hester S A Oldenburg; Gabe S Sonke; Danielle McCool; Flora E van Leeuwen; Koen K Van de Vijver; Nicola S Russell; Sabine C Linn; Sabine Siesling; C Willemien Menke-van der Houven van Oordt; Marjanka K Schmidt Journal: J Natl Cancer Inst Date: 2019-07-01 Impact factor: 13.506
Authors: Marc D Ryser; Donald L Weaver; Fengmin Zhao; Mathias Worni; Lars J Grimm; Roman Gulati; Ruth Etzioni; Terry Hyslop; Sandra J Lee; E Shelley Hwang Journal: J Natl Cancer Inst Date: 2019-09-01 Impact factor: 13.506
Authors: Julia A Knight; Leslie Bernstein; Joan Largent; Marinela Capanu; Colin B Begg; Lene Mellemkjaer; Charles F Lynch; Kathleen E Malone; Anne S Reiner; Xiaolin Liang; Robert W Haile; John D Boice; Jonine L Bernstein Journal: Am J Epidemiol Date: 2009-02-11 Impact factor: 4.897
Authors: Alexandra J van den Broek; Laura J van 't Veer; Maartje J Hooning; Sten Cornelissen; Annegien Broeks; Emiel J Rutgers; Vincent T H B M Smit; Cees J Cornelisse; Mike van Beek; Maryska L Janssen-Heijnen; Caroline Seynaeve; Pieter J Westenend; Jan J Jobsen; Sabine Siesling; Rob A E M Tollenaar; Flora E van Leeuwen; Marjanka K Schmidt Journal: J Clin Oncol Date: 2015-12-23 Impact factor: 44.544
Authors: Andrea M Covelli; Nancy N Baxter; Margaret I Fitch; David R McCready; Frances C Wright Journal: Ann Surg Oncol Date: 2014-09-05 Impact factor: 5.344
Authors: Anne S Reiner; Charles F Lynch; Julia S Sisti; Esther M John; Jennifer D Brooks; Leslie Bernstein; Julia A Knight; Li Hsu; Patrick Concannon; Lene Mellemkjær; Marc Tischkowitz; Robert W Haile; Ronglai Shen; Kathleen E Malone; Meghan Woods; Xiaolin Liang; Monica Morrow; Jonine L Bernstein Journal: Breast Cancer Res Date: 2017-07-19 Impact factor: 6.466
Authors: D Brock Hewitt; Yaming Li; Oindrila Bhattacharyya; James L Fisher; Daniel Stover; Samilia Obeng-Gyasi Journal: J Racial Ethn Health Disparities Date: 2022-04-06